| Literature DB >> 32590991 |
Naoko Kaneko1,2, Sayuri Nakamura3, Kazunobu Sawamoto4,5.
Abstract
In many mammalian species, the production of new neurons in the hippocampal dentate gyrus continues throughout life. Previous studies using rodents suggest that adult-born neurons are involved in memory and cognition tasks and mood regulation. Interferon-alpha (IFNα), a proinflammatory cytokine used for the treatment of chronic viral hepatitis and malignancies, frequently causes depressive symptoms in patients and animals, including non-human primates. We have previously demonstrated that chronic IFNα treatment decreases hippocampal neurogenesis in mice. Here, we investigated the effects of four-week human pegylated IFNα treatment on hippocampal neurogenesis and behavior in common marmosets. Continuous monitoring of voluntary activity levels using an actigraphy device suggested that adaptive ability is impaired in IFNα-treated animals. Analyses of BrdU-labeled cells expressing a marker for immature or mature neurons revealed a significant reduction in the number of new neurons in the hippocampus of IFNα-treated animals. These data indicate that chronic human IFNα treatment causes behavioral changes and a decrease in hippocampal neurogenesis in common marmosets.Entities:
Keywords: Adult neurogenesis; Common marmoset; Dentate gyrus; Depression; Interferon-alpha; Primate; Proliferation
Mesh:
Substances:
Year: 2020 PMID: 32590991 PMCID: PMC7318457 DOI: 10.1186/s13041-020-00639-9
Source DB: PubMed Journal: Mol Brain ISSN: 1756-6606 Impact factor: 4.041
Fig. 1Effects of IFNα on behavioral activity and hippocampal neurogenesis in common marmosets. a: Experimental procedures. Adult common marmosets were treated with human pegylated IFNα or vehicle (control, Cnt) once a week for 4 weeks (see Materials and Methods in supplemental information), and BrdU was injected once a day for the first 10 consecutive days. The voluntary activity of each animal was continuously monitored by actigraphy from the day before (− 1d) treatment to the end of the experimental period. The animal tissues were fixed at day 28 for histological analyses. b: Mean bodyweight of the animals in the control and IFNα-treated groups before (on day − 1) and during drug administration (on day 7, 14, 21, and 28). c-c’: Daytime (c) and nighttime (c’) mean activity counts of animals for 10 days after fitting the actigraphy device. d-d’: Daytime (d) and nighttime (d’) mean activity counts of animals a day before (−1d) and each week during IFNα or vehicle treatment. e-f: Representative images of BrdU-labeled (BrdU+) cells in the SGZ and GCL of the dentate gyrus. The Z-stack projection image shows BrdU+ cells (magenta) expressing Dcx (green) (e). Confocal image showing a BrdU+ cell (red) expressing NeuN (cyan) (f). The x-z and y-z planes are presented in the top and right panels, respectively. g-h: Z-stack projection images of the dentate gyrus immunostained for BrdU (magenta), Dcx (green), and NeuN (blue) in control (g) and IFNα-treated (h) animals. High-magnification images of the boxed areas in (g) and (h) are shown in (g’) and (h’), respectively (BrdU: magenta, Dcx: green, The x-z and y-z planes are presented in the top and right panels, respectively). i: The number of BrdU+ cells that express Dcx or NeuN in the dentate gyrus (SGZ and GCL). Scale bars: 10 μm (e-h’). The quantitative data are presented as the mean ± SEM. *P < 0.05, **P < 0.01